Aurora Cannabis Inc.

Aurora Cannabis Inc.(ACB)股票分析

$4.170

-0.117 (-2.80%)收盘时

Loading chart…
最高
4.310
开盘
4.200
成交量加权均价
4.21
成交量
1.18M
市值
258.02M
最低
4.135
成交额
4.95M
企业价值/息税折旧摊销前利润(TTM)
-6.10

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally. The Company operates through its Cannabis segment. The Cannabis segment comprises the Canadian, Europe, Australian and New Zealand CGUs. The Company offers cannabis products including dried flower, pre-rolls, infused pre-rolls, capsules, cannabis oils, concentrates, vapes, edibles, beverages, and topicals. Its brands include Aurora, MedReleaf, Pedanios, San Raf, WMMC, Tasty's, and others. The Company is engaged in distributing wholesale medical cannabis in various international markets, including Australia and New Zealand. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., and ACB Captive Insurance Company Inc., among others.

AI 分析 of Aurora Cannabis Inc. (ACB)

买入

Aurora Cannabis Inc is a good buy right now, trading at $4.49, with a recent RSI of 69.36 indicating strong momentum. The stock has seen a 14.54% increase over the past 5 days, suggesting positive short-term momentum. Additionally, the company has a gross margin of 47.68% in its latest quarter, which is significantly higher than previous quarters, indicating improved operational efficiency. However, the main risk is the ongoing hostile takeover bid from Curaleaf, which could lead to volatility in the stock price.

估值指标

Aurora Cannabis Inc.(ACB)当前预期市盈率为 109.89,5 年平均预期市盈率为 -47.18。

预期市盈率

合理
5 年均值 P/E
-47.18
当前P/E
109.89
高估
306.85
低估
-401.21

预期 EV/EBITDA

合理
5 年均值 EV/EBITDA
0.15
当前EV/EBITDA
-6.10
高估
41.60
低估
-41.30

预期市销率

合理
5 年均值 P/S
1.72
当前P/S
0.86
高估
3.23
低估
0.21

Alphio AI 对 ACB 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%ACB

$8.45

情景价格

基

基准

基准 · 50%ACB

$7.70

情景价格

悲

悲观

悲观 · 25%ACB

$6.10

情景价格

事件时间线

2026-10-14 (ET)

16:00:00

Aurora Cannabis Recommends Shareholders Reject Curaleaf's Acquisition Offer

16:00:00

Aurora Cannabis Explores Alternatives to Surpass Curaleaf's Acquisition Bid

2026-10-08 (ET)

07:30:00

Aurora Cannabis Completes Facility Expansion in Leuna, Germany

2026-10-06 (ET)

17:00:00

Aurora Cannabis Responds to Curaleaf's Takeover Bid

12:00:00

Curaleaf Increases Offer to Acquire Aurora to $6

资讯

ACB 常见问题 —— 由 Alphio AI 解答

Aurora Cannabis Inc. is a Canada-based medical cannabis company. The Company's principal business lines are focused on the production, distribution and sale of cannabis and cannabis-derivative products in Canada and internationally. The Company operates through its Cannabis segment. The Cannabis segment comprises the Canadian, Europe, Australian and New Zealand CGUs. The Company offers cannabis products including dried flower, pre-rolls, infused pre-rolls, capsules, cannabis oils, concentrates, vapes, edibles, beverages, and topicals. Its brands include Aurora, MedReleaf, Pedanios, San Raf, WMMC, Tasty's, and others. The Company is engaged in distributing wholesale medical cannabis in various international markets, including Australia and New Zealand. Its subsidiaries include Aurora Cannabis Enterprises Inc., Aurora Deutschland GmbH, Whistler Medical Marijuana Corporation, and Indica Industries Pty Ltd., and ACB Captive Insurance Company Inc., among others. It operates in the Healthcare sector (MEDICINAL CHEMICALS AND BOTANICAL PRODUCTS industry).

Aurora Cannabis Inc is a good buy right now, trading at $4.49, with a recent RSI of 69.36 indicating strong momentum. The stock has seen a 14.54% increase over the past 5 days, suggesting positive short-term momentum. Additionally, the company has a gross margin of 47.68% in its latest quarter, which is significantly higher than previous quarters, indicating improved operational efficiency. However, the main risk is the ongoing hostile takeover bid from Curaleaf, which could lead to volatility in the stock price.

jadeprism972026/10/5

$ACB Curaleaf is offering about 1.5x sales for this struggling cannabis company. Take the money and shift into the better stock.

展开
注册或登录后参与讨论

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易